Boosting with intranasal dendrimeric Aβ1–15 but not Aβ1–15 peptide leads to an effective immune response following a single injection of Aβ1–40/42 in APP-tg mice

BACKGROUND: Immunotherapy for Alzheimer's disease (AD) is emerging as a potential treatment. However, a clinical trial (AN1792) was halted after adverse effects occurred in a small subset of subjects, which may have been caused by a T cell-mediated immunological response. In general, aging limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Seabrook, Timothy J, Jiang, Liying, Thomas, Katelyn, Lemere, Cynthia A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550385/
https://www.ncbi.nlm.nih.gov/pubmed/16753065
http://dx.doi.org/10.1186/1742-2094-3-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550385/
https://www.ncbi.nlm.nih.gov/pubmed/16753065
http://dx.doi.org/10.1186/1742-2094-3-14

Ejemplares similares